PMA Post-Approval Requirements and Supplement Obligations

The Approval Order Is the Starting Line, Not the Finish Line

When FDA issues a Premarket Approval (PMA) order under 21 CFR Part 814, it does not simply grant permission to sell a device and walk away. The approval order is the beginning of a long-term regulatory relationship. It imposes conditions — specific post-approval requirements that the PMA holder must fulfill to maintain valid approval status and to remain in compliance with the Federal Food, Drug, and Cosmetic Act.

These obligations span reporting, surveillance, manufacturing, and change control. Companies that treat PMA approval as a one-time milestone and neglect the post-market infrastructure often find themselves facing Warning Letters, untitled letters, or, in the most serious cases, consent decrees years after approval. Understanding what is required — and building the quality system infrastructure to manage it — is as important as preparing the original submission.

This guide covers the four core categories of ongoing obligation that every PMA holder faces: periodic reporting, post-approval studies, MDR requirements, and PMA supplement obligations for device or process changes.

Post-Approval Conditions Imposed at Approval

The FDA approval order itself will specify any conditions unique to the device. These may include restrictions on the indicated patient population, requirements to train physicians or facilities before commercial distribution, limitations on the number of sites that may implant or use the device, or commitments to continue collecting clinical data.

Conditions of approval are legally binding. A PMA holder that deviates from them — for example, by distributing to providers who have not received the required training, or by failing to complete a registry commitment — is in violation of the approval order, not merely out of compliance with guidance. FDA enforcement in this area can be swift and consequential.

Before finalizing an approval order negotiation, PMA holders should carefully read every condition, assess whether each is operationally feasible, and flag anything that will require system or process changes to the regulatory and quality teams. Some conditions are boilerplate; others are device-specific and require careful interpretation.

Periodic Reporting: Annual and Biennial Reports

Under 21 CFR 814.84, every PMA holder must submit periodic reports to FDA. For most PMA devices, FDA requires an annual report submitted within 30 days of the anniversary of the original approval date. Devices approved under certain conditions may require reports on a biennial cycle — the approval order will specify the schedule.

The annual report must include:

• A summary of MDRs submitted during the reporting period, including any patterns or trends in adverse events or malfunctions
• A bibliography of published and unpublished reports known to the PMA holder that bear on the device's safety or effectiveness
• Copies of any new safety and effectiveness data from clinical investigations or nonclinical studies completed during the reporting period
• Changes made under the Minor Modifications category that do not require a supplement — these must be reported here if they would otherwise require a 30-Day Notice but were implemented before submission
• Information required by any device-specific conditions of approval, such as post-approval study enrollment data or adverse event registry data

Missing an annual report filing date is a reportable deviation and a compliance vulnerability. Many companies set an internal reminder 90 days before the anniversary date to begin compiling the report, so they are not scrambling during the 30-day window.

PMA Supplements: When Changes Require Submission

This is the area that generates the most confusion for PMA holders and where errors are most costly. Under 21 CFR 814.39, any change to a PMA-approved device that could affect safety or effectiveness must be submitted to FDA as a supplement — and FDA must approve the supplement before the change may be implemented, unless the change qualifies for a 30-Day Notice pathway.

The categories of change that require a supplement include, but are not limited to:

• Changes to the device's design, components, materials, or principle of operation
• Changes to manufacturing procedures, manufacturing sites, or suppliers of critical components
• Changes to the sterilization method or validation
• New or revised indications for use
• New contraindications, warnings, or labeling changes that are not minor editorial corrections
• Changes to the packaging or shelf life if supported by new test data

The critical question is always: does this change require a supplement, and if so, which type? The answer determines your timeline for implementation. Getting this wrong in either direction has consequences: implementing a change that required a supplement before FDA approves it is a serious violation; over-classifying a minor change as a Panel Track submission wastes resources and delays implementation unnecessarily.

The Four Supplement Types Compared

FDA regulation and guidance establish a tiered supplement structure. Each tier corresponds to the degree of change and the expected level of FDA review intensity.

Panel Track Supplements

A Panel Track Supplement is the most resource-intensive supplement type and is required when a proposed change is substantial enough that FDA may need to convene an advisory panel to review the new evidence. Classic triggers include a new indication for use that expands the intended patient population, a new contraindication, or a design change so fundamental that it alters the operating principle of the device and requires new clinical study data.

The Panel Track designation is FDA's determination, not the applicant's. However, applicants can seek input through the Pre-Submission program before filing to clarify whether a proposed change is likely to be routed as a Panel Track. Given the timeline implications — a 180-day target that often extends longer in practice when deficiency letters are issued — early FDA engagement is strongly advisable for any change of significant scope.

180-Day Supplements

The 180-Day Supplement covers a broad middle ground of changes that are meaningful enough to require FDA review and approval before implementation, but not so significant that an advisory panel is expected. Examples include changes to sterilization methods supported by new validation data, modifications to the sterile packaging system, new test methods for quality release, and substantial redesigns of components that do not alter the device's principle of operation.

FDA targets a 180-day review clock for these submissions, though applicants should plan for that timeline and build a change management buffer accordingly. A thorough 180-Day Supplement — with well-organized supporting data, a clear summary of the change, and an explicit risk assessment — reduces the likelihood of a major deficiency that stops the review clock and extends the timeline further.

Real-Time Supplements

Real-Time Supplements are reserved for minor changes accompanied by supporting data where the benefit-risk profile is well characterized and the change is not expected to introduce new safety signals. FDA targets a 30-day review for Real-Time Supplements and conducts an expedited review. Eligible changes typically include minor design modifications with well-controlled bench testing, limited labeling revisions, or component substitutions where the replacement is materially equivalent and supported by comparative data.

Companies should not reflexively classify a change as Real-Time to accelerate implementation timelines. The classification must be supported by a documented change assessment in the quality system. FDA reviewers can reclassify a Real-Time Supplement as a 180-Day Supplement if they determine the change warrants more extensive review, resetting the clock.

30-Day Notice for Manufacturing Site Changes

The 30-Day Notice pathway under 21 CFR 814.39(f) is available for certain manufacturing site additions or transfers where the process and equipment are the same and the manufacturing is already covered by a valid FDA establishment registration. The PMA holder may implement the change 30 days after submitting the notice to FDA, provided FDA does not object within that period.

This pathway is narrower than it may appear. Not all manufacturing site changes qualify — complex biologics-based devices, unique processes, or changes where the site has not previously been inspected may require a full supplement. The decision to proceed as a 30-Day Notice should be made with regulatory counsel and documented in the change management record.

Post-Approval Studies: Ongoing Clinical Obligations

FDA may impose a Post-Approval Study (PAS) as a condition of PMA approval when the pre-approval clinical evidence was insufficient to fully characterize the device's long-term performance, characterize rare adverse events, or evaluate specific subpopulations. The PAS is not optional — it is a legally binding condition of the approval order.

The PAS protocol specifies the study objectives, study design, enrollment targets, primary and secondary endpoints, and the reporting schedule for progress reports to FDA. PMA holders must submit annual progress reports covering patient enrollment, protocol deviations, adverse events, and any interim analyses. Final study results must be submitted to FDA upon study completion.

FDA's post-approval study tracking program monitors PAS completion rates across device types, and companies that fall behind on enrollment or reporting will receive formal correspondence. In some cases, FDA has issued Warning Letters for failure to complete PAS obligations or for submitting progress reports late or with inadequate data.

Companies should designate a PAS coordinator within the clinical or regulatory function, maintain a living protocol document, and integrate PAS milestones into the device lifecycle management calendar from day one of approval.

Medical Device Reporting After PMA Approval

Under 21 CFR Part 803, manufacturers — including PMA holders — must report certain adverse events and device malfunctions to FDA through the Medical Device Reporting (MDR) system. The mandatory reporting timelines are:

• 30-day reports: For events where a device may have caused or contributed to a serious injury or death, or where a malfunction occurred that could cause or contribute to serious injury or death if it were to recur
• 5-day reports: For events requiring remedial action to prevent unreasonable risk of substantial harm, or events that FDA has designated as requiring expedited reporting under a specific order
• Baseline reports: Required the first time a device type is the subject of an MDR, and updated annually if the baseline information changes

The MDR obligation for PMA holders is often more closely scrutinized than for 510(k) devices, because Class III devices typically carry higher inherent risk and are subject to more intense post-market surveillance. PMA holders should have a written MDR procedure, a trained MDR intake team, and a documented decision tree for evaluating adverse events and complaints against the Part 803 reporting thresholds.

MDR data is public — reports are accessible through FDA's MAUDE database. Patterns of adverse events or malfunctions in a PMA holder's MDR history can trigger FDA inspections, requests for post-market studies, or labeling changes. Proactive monitoring of MAUDE data for your own device, and for comparable devices from competitors, is a sound post-market surveillance practice.

Manufacturing Site Inspections After PMA Approval

PMA approval does not insulate a manufacturer from ongoing FDA inspections. Under 21 CFR 820 (Quality System Regulation) and the successor Quality Management System Regulation (QMSR), FDA inspects PMA holders' manufacturing sites on a routine basis — typically every two years for Class III devices, though the frequency may increase based on compliance history or adverse event signals.

Pre-Approval Inspections (PAIs) occur before the PMA is approved. Post-approval, the same facilities may be inspected as part of FDA's routine biennial inspection schedule, or may be triggered by a PMA Supplement that proposes a significant manufacturing change. A manufacturing site that received a clean PAI can still receive a 483 observation or Warning Letter years later if quality system processes have degraded.

Maintaining inspection readiness is a continuous discipline, not a pre-approval sprint. PMA holders should conduct internal audits on a documented schedule, address CAPA items arising from internal audits before they become systemic, and ensure that all required Device History Records (DHRs) and Manufacturing Records are complete and retrievable. A well-maintained quality system is the most durable post-approval investment a Class III manufacturer can make.

Frequently Asked Questions

What is a PMA Supplement?

A PMA Supplement is a submission to FDA required whenever an approved PMA holder makes a change to the device, its manufacturing process, labeling, or indications for use. Under 21 CFR 814.39, virtually any change that could affect safety or effectiveness must be submitted as a supplement before implementation — unless it qualifies as a 30-Day Notice or a Minor Modification reportable in the next annual report.

When do I need a Panel Track versus a 180-Day PMA Supplement?

A Panel Track Supplement is required when a proposed change is so significant that it may require new clinical data and potential review by an advisory panel — for example, a new indication for use or a major design change that alters the fundamental operating principle. A 180-Day Supplement covers moderate changes, such as new sterilization processes or substantial manufacturing modifications, where FDA reviews new data but an advisory panel convening is unlikely.

What triggers a post-approval study requirement?

FDA may impose a post-approval study (PAS) as a condition of PMA approval when the clinical evidence at the time of approval was insufficient to fully characterize long-term performance, rare adverse events, or the device's benefit-risk profile in specific subpopulations. The PAS protocol, enrollment milestones, and reporting schedule are specified in the approval order, and annual progress reports to FDA are mandatory.

What are my MDR obligations after PMA approval?

Under 21 CFR Part 803, PMA holders must submit Medical Device Reports (MDRs) to FDA for any event that caused or contributed to a serious injury, death, or device malfunction that could cause or contribute to serious injury or death if it recurred. Mandatory reporters (manufacturers) must submit within 30 calendar days for most events, or within 5 days for events requiring remedial action to prevent unreasonable risk of substantial harm.